c-Met inhibitor
Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities
... aberrant c-Met activation has been implicated in a variety of human cancers for its critical role in tumor growth, metastasis and tumor ...Thus, c-Met axis presents as an attractive ...
14
The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor
... against c-Met-dependent malignancies, the research presented herein reports on the discovery of the novel olive-derived homovanillyl sinapate (HVS) as a promising c-Met ...wild-type ...
27
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
... multikinase inhibitor of Raf, VEGF and PDGF receptor signaling is approved for advanced hepatocellular carcinoma ...novel c-Met inhibitor, DE605, together with sorafenib in hepatocellular ...
17
c-Met Inhibitor Synergizes with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Papillary Thyroid Carcinoma Cell Death
... It has been shown that a number of compounds generate ROS-induced cell death (32), and DR5 expression is upreg- ulated by ROS (33). A recent study con- ducted by our group demonstrated that PHA665752 induces DR5 ...
11
BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1
... protease inhibitor cocktail (Cat ...(#3077), c-Met (#8198), phospho-AKT (#9271), AKT (#9272), phospho-ERK1/2 (#4370), ERK1/2 (#9102), β-actin (#3700), E-cadherin (#3195), N-cadherin (#13116), and ...
13
<p>Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma</p>
... antibody-based c-Met inhibitor is still ...cause c-Met activation, such as overexpression-induced activation, mutation-induced activation, or transactivation of other ...
12
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
... In Asia, lung cancer is the most frequent malignant tumour in males and the second most frequent in females. 1 About 85% of lung cancer is classi fi ed into non-small-cell lung cancer (NSCLC), and activating epidermal ...
8
<p>MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis</p>
... competitive c-MET ...with MET GCN ≥ 4 was 26% and ...and MET FISH-positive (>5, HR = ...high MET expression (MET GCN ≥ ...
20
<p>Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling</p>
... including c-Met and ...among c-MET-ampli fi ed cell lines. In a previous study, CD44 inhibitor drugs were screened using qRT-PCR analysis of MKN45 cells with CSCs to determine their ...
9
c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications
... Another c-Met inhibitor, Crizotinib (PF-02341066), represents a designed tyrosine kinase inhibitor based on the core structure of the c-Met-inhibitor PHA 665752 in which ...
9
The clinical and functional significance of c Met in breast cancer: a review
... Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor is regarded as a novel therapeutic ...of c-Met signalling in different models of breast development ...
11
Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
... We next tried to explore whether cotargeting of EGFR and c-MET could overcome the acquired resistance to erlotinib in human tongue cancer. For this purpose, the resistant cells were treated by SU11274 (5 µ ...
10
The role of HGF/c-MET signaling pathway in lymphoma
... oncogenic c-MET ...the c-MET- epidermal growth factor receptor (EGFR), c-MET- vascular endothelial growth factor receptor (VEGFR), and c-MET-Wnt pathways has also ...
8
Overexpression of <em>PI3K p110α</em> contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
... α inhibitor PI-103 and MET selective inhibitor PHA665752 were purchased from Selleck Chemi- cals (Houston, TX, ...phosphatase inhibitor cocktails were purchased from Sigma-Aldrich (St Louis, ...
8
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
... hepatitis C virus ...an inhibitor of HCV nonstructural 3 ...NS5A inhibitor, asunaprevir results in a very high rate of viral eradication in both treatment-naïve and treatment-experienced patients, ...
12
The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction
... of C-MET, p-C-MET, AKT, and p-AKT proteins were higher in all of the treatment groups and were maximized in those groups receiving irradiation before administration; the lowest levels were ...
6
MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
... for MET exon 14 skipping. Patients with MET exon 14 skipping displayed unique characteristics: female, non- smokers, earlier pathology stage and older ...age. MET exon 14 skipping indicated an early ...
12
HGF/c-Met related activation of β-catenin in hepatoblastoma
... Briefly, 4 μ m TMA slides were deparaffinized with xylene and ethanol. Antigen retrieval was performed by pressure cooking for 2 minutes in citrate buffer pH6.0. Endogenous peroxidases were blocked with 0.3% hydro- gen ...
10
Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer
... increased c-MET levels are found in CRC liver ...of c-MET at both protein and mRNA levels in several invasive CRC ...of c-MET using RNAi suppressed migration/invasion of parental ...
14
Original Article Expression of MACC1-1 and c-Met in human prostatic cancer and their clinicopathological significance
... and c-Met are overexpression in PCa, and their overexpres- sion correlate to poor prognosis in PCa ...and c-Met may help for the auxiliary diagnosis of bladder cancer and judg- ing the ...
7